NO20035025L - Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. - Google Patents
Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.Info
- Publication number
- NO20035025L NO20035025L NO20035025A NO20035025A NO20035025L NO 20035025 L NO20035025 L NO 20035025L NO 20035025 A NO20035025 A NO 20035025A NO 20035025 A NO20035025 A NO 20035025A NO 20035025 L NO20035025 L NO 20035025L
- Authority
- NO
- Norway
- Prior art keywords
- osteopontin
- prevention
- treatment
- antagonist
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111296 | 2001-05-17 | ||
PCT/EP2002/005081 WO2002092122A2 (en) | 2001-05-17 | 2002-05-08 | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20035025D0 NO20035025D0 (no) | 2003-11-12 |
NO20035025L true NO20035025L (no) | 2003-11-12 |
Family
ID=8177366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035025A NO20035025L (no) | 2001-05-17 | 2003-11-12 | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. |
Country Status (27)
Country | Link |
---|---|
US (4) | US7217687B2 (no) |
EP (1) | EP1389130B1 (no) |
JP (2) | JP4417632B2 (no) |
KR (1) | KR100947424B1 (no) |
CN (2) | CN1286524C (no) |
AT (1) | ATE555803T1 (no) |
AU (1) | AU2002312886B2 (no) |
BG (1) | BG108337A (no) |
BR (1) | BR0209812A (no) |
CA (1) | CA2443964A1 (no) |
CZ (1) | CZ20033109A3 (no) |
EA (1) | EA006655B1 (no) |
EE (1) | EE200300559A (no) |
ES (1) | ES2387082T3 (no) |
HK (1) | HK1067051A1 (no) |
HR (1) | HRP20030840A2 (no) |
HU (1) | HUP0400005A3 (no) |
IL (2) | IL158867A0 (no) |
MX (1) | MXPA03010327A (no) |
NO (1) | NO20035025L (no) |
NZ (1) | NZ528852A (no) |
PL (1) | PL211763B1 (no) |
SK (1) | SK14232003A3 (no) |
UA (1) | UA85368C2 (no) |
WO (1) | WO2002092122A2 (no) |
YU (1) | YU89503A (no) |
ZA (1) | ZA200307956B (no) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004532633A (ja) * | 2001-05-09 | 2004-10-28 | ビオ・ビジョン・アーゲー | 進行性の慢性痴呆疾患の検出方法、これに適したペプチド及び検出試薬 |
US7282490B2 (en) | 2001-11-21 | 2007-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
CN1662249A (zh) * | 2002-06-25 | 2005-08-31 | 安万特药物公司 | 骨桥蛋白、少突神经胶质细胞和髓鞘形成 |
US7678889B2 (en) * | 2002-08-06 | 2010-03-16 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
CN1791422A (zh) * | 2003-03-28 | 2006-06-21 | 应用研究系统Ars股份公司 | 凝聚素在治疗和/或预防周围神经疾病中的用途 |
WO2005025333A1 (en) * | 2003-09-18 | 2005-03-24 | Arla Foods Amba | Infant formula |
JP5456235B2 (ja) * | 2003-11-12 | 2014-03-26 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経変性疾患を治療するためのワクチン及び方法 |
EP1848453B1 (en) * | 2005-02-18 | 2010-10-27 | Proximagen Ltd. | Treatment for neurodegeneration |
US20060264371A1 (en) * | 2005-02-18 | 2006-11-23 | Proximagen Ltd. | Treatment |
US8071376B2 (en) | 2005-10-13 | 2011-12-06 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
WO2008086449A2 (en) * | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
US20100069254A1 (en) * | 2008-09-16 | 2010-03-18 | Laree Hiser | Cell Culture Model for Demyelination/Remyelination |
KR101449100B1 (ko) * | 2011-04-21 | 2014-10-13 | 가톨릭대학교 산학협력단 | 신경세포 데브리스 제거용 오스테오폰틴 |
GB2493540A (en) * | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
KR101728808B1 (ko) * | 2012-09-28 | 2017-04-20 | 한국생명공학연구원 | 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
US20170269076A1 (en) * | 2014-08-27 | 2017-09-21 | Dana-Farber Cancer Institute, Inc. | Intracellular osteopontin regulates the lineage commitment of lymphoid subsets |
EP3458036B1 (en) * | 2016-05-20 | 2023-08-23 | Cedars-Sinai Medical Center | Treating or preventing alzheimer's disease and associated conditions |
EP3544994A4 (en) * | 2016-11-27 | 2020-06-03 | Triton Algae Innovations, Inc. | METHOD FOR PURIFYING RECOMBINANT OSTEOPONTIN FROM MICROALGAES |
MX2019013096A (es) | 2017-05-04 | 2019-12-16 | Follicum Ab | Peptidos para el tratamiento de diabetes. |
CN111315394A (zh) * | 2017-08-15 | 2020-06-19 | 儿童医疗中心有限公司 | 作为用于神经元病变的治疗剂的骨桥蛋白 |
TR201903865A2 (tr) * | 2019-03-14 | 2020-09-21 | Bogazici Ueniversitesi | Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi |
WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
CN111388654A (zh) * | 2020-05-22 | 2020-07-10 | 南通大学 | 治疗脊髓损伤的药物、药物试剂盒及方法 |
US20230265435A1 (en) * | 2020-06-02 | 2023-08-24 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Composition comprising osteopontin inhibitor as active ingredient for prevention, alleviation, or treatment of neurodegenerative disease |
CN117720620A (zh) * | 2023-12-13 | 2024-03-19 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2355976C (en) * | 1998-12-22 | 2012-07-17 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
CA2370129A1 (en) | 1999-04-15 | 2000-10-26 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
WO2000064460A2 (en) | 1999-04-23 | 2000-11-02 | Sulzer Orthopedics Ltd. | Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin |
KR100619612B1 (ko) | 1999-10-04 | 2006-09-01 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 폴리머 안정화 신경펩타이드 |
-
2002
- 2002-05-08 IL IL15886702A patent/IL158867A0/xx unknown
- 2002-05-08 SK SK1423-2003A patent/SK14232003A3/sk unknown
- 2002-05-08 BR BR0209812-1A patent/BR0209812A/pt not_active IP Right Cessation
- 2002-05-08 UA UA20031110269A patent/UA85368C2/ru unknown
- 2002-05-08 MX MXPA03010327A patent/MXPA03010327A/es active IP Right Grant
- 2002-05-08 ES ES02738042T patent/ES2387082T3/es not_active Expired - Lifetime
- 2002-05-08 WO PCT/EP2002/005081 patent/WO2002092122A2/en active Application Filing
- 2002-05-08 CA CA002443964A patent/CA2443964A1/en not_active Abandoned
- 2002-05-08 JP JP2002589038A patent/JP4417632B2/ja not_active Expired - Fee Related
- 2002-05-08 NZ NZ528852A patent/NZ528852A/en not_active IP Right Cessation
- 2002-05-08 CN CNB028144627A patent/CN1286524C/zh not_active Expired - Fee Related
- 2002-05-08 EP EP02738042A patent/EP1389130B1/en not_active Expired - Lifetime
- 2002-05-08 CZ CZ20033109A patent/CZ20033109A3/cs unknown
- 2002-05-08 KR KR1020037014773A patent/KR100947424B1/ko not_active IP Right Cessation
- 2002-05-08 EA EA200301253A patent/EA006655B1/ru not_active IP Right Cessation
- 2002-05-08 AT AT02738042T patent/ATE555803T1/de active
- 2002-05-08 CN CNA2006101317669A patent/CN1939538A/zh active Pending
- 2002-05-08 EE EEP200300559A patent/EE200300559A/xx unknown
- 2002-05-08 US US10/477,876 patent/US7217687B2/en not_active Expired - Fee Related
- 2002-05-08 PL PL367065A patent/PL211763B1/pl not_active IP Right Cessation
- 2002-05-08 HU HU0400005A patent/HUP0400005A3/hu unknown
- 2002-05-08 YU YU89503A patent/YU89503A/sh unknown
- 2002-05-08 AU AU2002312886A patent/AU2002312886B2/en not_active Ceased
-
2003
- 2003-10-13 ZA ZA200307956A patent/ZA200307956B/en unknown
- 2003-10-15 HR HR20030840A patent/HRP20030840A2/hr not_active Application Discontinuation
- 2003-11-10 BG BG108337A patent/BG108337A/bg unknown
- 2003-11-12 NO NO20035025A patent/NO20035025L/no not_active Application Discontinuation
- 2003-11-13 IL IL158867A patent/IL158867A/en not_active IP Right Cessation
-
2004
- 2004-11-05 US US10/981,737 patent/US7297099B2/en not_active Expired - Fee Related
- 2004-12-22 HK HK04110138A patent/HK1067051A1/xx not_active IP Right Cessation
-
2007
- 2007-02-27 US US11/679,735 patent/US20070225214A1/en not_active Abandoned
- 2007-11-07 US US11/936,623 patent/US20080213234A1/en not_active Abandoned
-
2009
- 2009-06-05 JP JP2009136621A patent/JP5036761B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
EE200300440A (et) | Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks | |
CL2004001174A1 (es) | Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia | |
BR0308452A (pt) | composições farmacêuticas e métodos de preparação de composição farmacêutica | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
WO2006002437A3 (en) | Treatment of conditions involving demyelination | |
MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
MX2007004936A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1. | |
WO2003080582A3 (de) | Fredericamycin-derivate | |
TR200101859T2 (tr) | Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler | |
NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
WO2004009062A3 (en) | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
DE60313004D1 (de) | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination | |
TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
EE05357B1 (et) | Tablett, mis sisaldab vhemalt kahte eristatavat segmenti, ning selle kasutamine | |
WO2005123113A3 (en) | Interferon compositions and methods of use thereof | |
EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
UA85187C2 (en) | 2-aminobenzoyl derivatives | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
EA200400296A1 (ru) | Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности | |
WO2003064394A8 (de) | 5-ring heterozyklen zur verwendung als antiviral mittel | |
EP1498145A4 (en) | LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |